* NOVAGALI *
2000 - IDF
Évry
(near Paris)
www.novagali.com Delivery, Drugs
Key words: Ophthalmology, Conjunctivitis, Dry eye, Glaucoma, Retinopathies, Novasorb, Eyeject, Cationorm
Mission: to develop a broad portfolio of innovative ophthalmic products addressing the numerous needs of patients suffering from ocular conditions
Clients: Pharmaceutical industry (own development up to registration)
novagali@novagali.com
Age: 11 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Start-up |
Managing Dir.-CEO: Martinez (Jérôme) [born 1960, Pharm.D., Pharmaco-economics, HEC, MBA, ex-Ethypharm, Lavipharm, Roussel Uclaf, Alliance Santé]
Sc.Dir.-CSO: Buggage (Ronald) [M.D., ex-Pfizer, Novartis]
Fin.Dir.-CFO: Parkinson (Philip) [MBA, ex-Nautilus Biotech, Pfizer]
R&D: Garrigue (Jean-Sébastien) [Pharm.D., MBA, ex-Batelle]
Financers (Hist.): CDC Enterprise Innovation, Auriga Ventures, 123 Multinova, FJCE (CDC), Crédit Agricole P.E., Edmond de Rothschild I.P., Siparex, Bernard Chauvin (B.A.) | Turnover (M€) : 0.43 (2009), 0.41 (2008), 0.02 (2006)
Total funding (M€) : 81.0
Last funding (M€) : 22.0
Focus : Ophthalmo
Position : Launch
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .09 | Acquisition by Santen (preliminary approval to acquire 100% stake for 102 M€) | ACQ- | [11 years] |
| 2011 .08 | Clinical trial (phase III) for Catioprost (completion, positive) | CLIN | [11 years] |
| 2011 .04 | Clinical trial (phase III) for Cyclokat, a new formulation of Cyclosporine, in dry eye (beginning) | CLIN | [10 years] |
| 2011 .01 | Registration : positive advice from EMA on Cyclokat Phase III clinical trial for the treatment of Dry Eye Disease | MKTG | [10 years] |
| 2010 .07 | Listing on Euronext Paris : 22.0 M€ | PBO | [9 years] |
| 2010 .04 | Financing (no interest loan) : 9.4 M€, by OSEO, as the lead project company (with Stanipharm, Crossject, and CNRS) on retinopathy for Vitrena | DEBT | [9 years] |
| 2009 .04 | Clinical trial (phase II) for with Cyclokat, a new formulation of Cyclosporine, in dry eye (completion) | CLIN | [8 years] |
| 2009 .02 | Research : positive in vivo toxicity evaluation of BAK-free latanoprost formulation for glaucoma | R&D | [8 years] |
| 2008 .12 | Registration : provisionally negative opinion from EMEA for lead compound Vekacia (non convincing results : dossier is withdrawn) | MKTG | [8 years] |
| 2008 .09 | 4th round-financing : 15.0 M€, by previous shareholders | RFIND | [8 years] |
| 2008 .04 | Launch of Cationorm on the French market, the first for the company | MKTG | [7 years] |
| 2007 .03 | Clinical trial (phase III) for Vekacia in Vernal Keratoconjonctivitis (VKC) (completed, positive) | CLIN | [6 years] |
| 2006 .04 | 3rd round-financing : 26.0 M€, with AGF P.E., Bernard Chauvin Group, and previous shareholders | RFINC | [5 years] |
| 2006 .01 | Clinical trial (phase II) for Cyclosporin derivative (completed) | CLIN | [5 years] |
| 2004 .12 | 2nd round-financing : 14.2 M€, with Edmond de Rothschild I.P., Siparex, and previous shareholders | RFINB | [4 years] |
| 2004 .09 | Nomination : Jérôme Martinez as CEO | ORGN | [4 years] |
| 2000 .09 | 1st round-financing : 3.8 M€, with CDC Enterprise Innovation, Auriga Ventures, 123 Multinova, FJCE (CDC), Crédit Agricole P.E. | RFINA | [0 year] |
| 2000 .08 | Company founded by Prof. Simon Benita (Israel) and others | ORGF | [0 year] | Actualisation / Updating: 28-Sep-2011 |
|
